Skip to main content

BIOMARCADORES PREDICTIVOS (ALTERACIONES GENETICAS, MICROAMBIENTE Y CARGA TUMORAL) EN LINFOMAS B AGRESIVOS CANDIDATOS A TRATAMIENTO INTENSIVO (TRASPLANTE O TERAPIA CON CELULAS CAR-T)

PI19/00887

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Execution centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL

  • Rivas Delgado, Alfredo|||0000-0003-0385-3415
  • López, Cristina
  • Clot, Guillem|||0000-0003-2588-7413
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Grau Vorster, Marta|||0000-0003-3779-0387
  • Frigola, Gerard|||0000-0001-6794-6456
  • Bosch-Schips, Jan
  • Radke, Josefine
  • Ishaque, Naveed|||0000-0002-8426-901X
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Luizaga Velasco, Luis|||0000-0001-9314-5783
  • Barcena, Carmen
  • Kelleher, Nicholas|||0000-0003-4610-2718
  • Villamor, Neus|||0000-0001-6538-4111
  • Baumann, Tycho|||0000-0003-4421-0088
  • Muntañola, Ana|||0000-0001-7839-6648
  • Sancho-Cia, Juan M.
  • Martín García-Sancho, Alejandro|||0000-0001-6330-1028
  • González Barca, Eva|||0000-0002-1323-1508
  • Matutes, Estella|||0000-0001-6745-7046
  • Brito, Jordi A.
  • Karube, Kennosuke
  • Salaverria Frigola, Itziar|||0000-0002-2427-9822
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Wiemann, Stefan|||0000-0003-4683-3174
  • Heppner, Frank L.
  • Siebert, Reiner
  • Climent, Fina|||0000-0002-4360-8388
  • Campo, Elias|||0000-0001-9850-9793
  • Giné, Eva|||0000-0002-0532-1204
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Bea, Sílvia|||0000-0001-7192-2385
Testicular large B-cell lymphoma (TLBCL) is an infrequent and aggressive lymphoma arising in an immune-privileged site and has recently been recognized as a distinct entity from diffuse large B-cell lymphoma (DLBCL). We describe the genetic features of TLBCL and compare them with published series of nodal DLBCL and primary large B-cell lymphomas of the CNS (PCNSL). We collected 61 patients with TLBCL. We performed targeted next-generation sequencing, copy number arrays, and fluorescent in situ hybridization to assess chromosomal rearrangements in 40 cases with available material. Seventy percent of the cases showed localized stages. BCL6 rearrangements were detected in 36% of cases, and no concomitant BCL2 and MYC rearrangements were found. TLBCL had fewer copy number alterations (p < 0.04) but more somatic variants (p < 0.02) than nodal DLBCL and had more frequent 18q21.32-q23 (BCL2) gains and 6q and 9p21.3 (CDKN2A/B) deletions. PIM1, MYD88, CD79B, TBL1XR1, MEF2B, CIITA, EP300, and ETV6 mutations were more frequent in TLBCL, and BCL10 mutations in nodal DLBCL. There were no major genetic differences between TLBCL and PCNSL. Localized or disseminated TLBCL displayed similar genomic profiles. Using LymphGen, the majority of cases were classified as MCD. However, we observed a subgroup of patients classified as BN2, both in localized and disseminated TLBCL, suggesting a degree of genetic heterogeneity in the TLBCL genetic profile. TLBCL has a distinctive genetic profile similar to PCNSL, supporting its recognition as a separate entity from DLBCL and might provide information to devise targeted therapeutic approaches.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation

  • Bastidas-Mora, Gabriela
  • Bea, Sílvia|||0000-0001-7192-2385
  • Navarro, Alba|||0000-0002-4041-0974
  • Giné, Eva|||0000-0002-0532-1204
  • Costa, Dolors|||0000-0002-8276-3292
  • Delgado, Julio|||0000-0002-5157-4376
  • Baumann, Tycho|||0000-0003-4421-0088
  • Magnano, Laura|||0000-0002-6928-8386
  • Rivas Delgado, Alfredo|||0000-0003-0385-3415
  • Villamor, Neus|||0000-0001-6538-4111
  • Colomer, Dolors|||0000-0001-7486-8484
  • López Guerra, Mónica|||0000-0002-5545-0178
  • Rozman, Maria|||0000-0002-2641-1110
  • Balagué, Olga|||0000-0002-5099-3675
  • Martínez Hernández, Daniel|||0000-0001-7492-5311
  • Baptista, Maria Joao|||0000-0003-3471-2535
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Blanes, Margarita
  • Climent, Fina|||0000-0002-4360-8388
  • Campo, Elias|||0000-0001-9850-9793
  • Wotherspoon, Andrew
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Matutes, Estella|||0000-0001-6745-7046
We describe 36 patients with splenic marginal zone lymphoma (SMZL) with transformation (SMZL-T), including 15 from a series of 84 patients with SMZL diagnosed at the Hospital Clinic of Barcelona (HCB) and 21 diagnosed with SMZL-T in other centres. In the HCB cohort, the cumulative incidence of transformation at 5 years was 15%. Predictors for transformation were cytopenias, hypoalbuminaemia, complex karyotype (CK) and both the Intergruppo Italiano Linfomi (ILL) and simplified Haemoglobin, Platelet count, lactate dehydrogenase (LDH) and extrahilar Lymphadenopathy (HPLL)/ABC scores (P < 0·05). The only independent predictor for transformation in multivariate analysis was CK [hazard ratio (HR) 4·025, P = 0·05]. Patients with SMZL-T had a significantly higher risk of death than the remainder (HR 3·89, P < 0·001). Of the 36 patients with SMZL-T, one developed Hodgkin lymphoma and 35 a diffuse large B-cell lymphoma, 71% with a non-germinal centre phenotype. The main features were B symptoms, lymphadenopathy, and high serum LDH. CK was observed in 12/22 (55%) SMZL-T and fluorescence in situ hybridisation detected abnormalities of MYC proto-oncogene, basic helix-loop-helix transcription factor (MYC), B-cell leukaemia/lymphoma 2 (BCL2) and/or BCL6 in six of 14 (43%). In all, 21 patients received immunochemotherapy, six chemotherapy, one radiotherapy and three splenectomy. The complete response (CR) rate was 61% and the median survival from transformation was 4·92 years. Predictors for a worse survival in multivariate analysis were high-risk International Prognostic Index (HR 5·294, P = 0·016) and lack of CR (HR 2·67, P < 0·001).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Unraveling the genetics of transformed splenic marginal zone lymphoma

  • Grau Vorster, Marta|||0000-0003-3779-0387
  • López, Cristina
  • Navarro, Alba|||0000-0002-4041-0974
  • Frigola, Gerard|||0000-0001-6794-6456
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Clot, Guillem|||0000-0003-2588-7413
  • Bastidas-Mora, Gabriela
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Baptista, Maria Joao|||0000-0003-3471-2535
  • Blanes, Margarita
  • Colomer, Dolors|||0000-0001-7486-8484
  • Costa, Dolors|||0000-0002-8276-3292
  • Domingo-Domenech, Eva|||0000-0001-8907-090X
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Forcada, Pilar
  • Giné, Eva|||0000-0002-0532-1204
  • López Guerra, Mónica|||0000-0002-5545-0178
  • Ramón, Olga
  • Rivas Delgado, Alfredo|||0000-0003-0385-3415
  • Folch, Laura Vicente
  • Wotherspoon, Andrew
  • Climent, Fina|||0000-0002-4360-8388
  • Campo, Elias|||0000-0001-9850-9793
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Matutes, Estella|||0000-0001-6745-7046
  • Bea, Sílvia|||0000-0001-7192-2385
The genetic mechanisms associated with splenic marginal zone lymphoma (SMZL) transformation are not well defined. We studied 41 patients with SMZL that eventually underwent large B-cell lymphoma transformation. Tumor material was obtained either only at diagnosis (9 patients), at diagnosis and transformation (18 patients), and only at transformation (14 patients). Samples were categorized in 2 groups: (1) at diagnosis (SMZL, n = 27 samples), and (2) at transformation (SMZL-T, n = 32 samples). Using copy number arrays and a next-generation sequencing custom panel, we identified that the main genomic alterations in SMZL-T involved TNFAIP3, KMT2D, TP53, ARID1A, KLF2, 1q gains, and losses of 9p21.3 (CDKN2A/B) and 7q31-q32. Compared with SMZL, SMZL-T had higher genomic complexity, and higher incidence of TNFAIP3 and TP53 alterations, 9p21.3 (CDKN2A/B) losses, and 6p gains. SMZL and SMZL-T clones arose by divergent evolution from a common altered precursor cell that acquired different genetic alterations in virtually all evaluable cases (92%, 12 of 13 cases). Using whole-genome sequencing of diagnostic and transformation samples in 1 patient, we observed that the SMZL-T sample carried more genomic aberrations than the diagnostic sample, identified a translocation t(14;19)(q32;q13) present in both samples, and detected a focal B2M deletion due to chromothripsis acquired at transformation. Survival analysis showed that KLF2 mutations, complex karyotype, and International Prognostic Index score at transformation were predictive of a shorter survival from transformation (P =.001; P =.042; and P =.007; respectively). In summary, SMZL-T are characterized by higher genomic complexity than SMZL, and characteristic genomic alterations that could represent key players in the transformation event.